Fig. 7. XAV939 administration ameliorates the abnormal behaviors in Pd1cKO mice.
A Illustration of XAV939 administration in embryonic mice. E13 Pd1cKO and littermate mice Pd1fl/fl mice were treated with XAV939 or DMSO until they were born. Six weeks later, the mice were subjected to behavioral analysis. B The immobile time of mice in the forced swimming test (DMSO group, n = 11 for Pd1fl/fl mice, n = 9 for Pd1cKO mice, and p = 0.041; XAV939 group, n = 7 for Pd1fl/fl mice, n = 11 for Pd1cKO mice, and p = 0.882). C Latency to immobility of mice in the forced swimming test (DMSO group, n = 11 for Pd1fl/fl mice, n = 8 for pd1cKO mice, and p = 0.0009; XAV939 group, n = 7 for Pd1fl/fl mice, n = 13 for Pd1cKO mice, and p = 0.502). D The total immobile time of mice in the tail suspension test (DMSO group, n = 11 for Pd1fl/fl mice, n = 8 for Pd1cKO mice, and p = 0.017; XAV939 group, n = 7 for Pd1fl/fl mice, n = 13 for Pd1cKO mice, and p = 0.725). E The sucrose consumption of mice in the sucrose preference test (DMSO group, n = 9 for Pd1fl/fl mice, n = 12 for Pd1cKO mice, p = 0.044; XAV939 group, n = 7 for Pd1fl/fl mice, n = 12 for Pd1cKO mice, and p = 0.206). F Statistic of the time that mice spend in the chambers with empty cylinder or with stranger mice 1 respectively (DMSO group, n = 11 for Pd1fl/fl mice, p = 0.0002; n = 9 for Pd1cKO mice, p = 0.108; XAV939 group, n = 7 for Pd1fl/fl mice, p = 0.041; n = 9 for Pd1cKO mice, and p = 0.0007). G Statistic of the time that mice spend in the chambers with stranger mice 1 or with stranger mice 2 respectively (DMSO group, n = 11 for Pd1fl/fl mice, p = 0.007; n = 9 for Pd1cKO mice, p = 0.792; XAV939 group, n = 7 for Pd1fl/fl mice, p = 0.036; n = 9 for Pd1cKO mice, and p = 0.018). H Time in the center in open field test (DMSO group, n = 10 for Pd1fl/fl mice, n = 13 for Pd1cKO mice, p = 0.0006; XAV939 group, n = 8 for Pd1fl/fl mice, n = 11 for Pd1cKO mice, and p = 0.248). Error bars represent means ± S.E.M.; one-way ANOVA, P < 0.05 (*), P < 0.01(**), and n.s. not significant.